SEELAS Life Sciences (SLS) - 2025 Q4 - Annual Results

Financial Position - As of December 31, 2025, SELLAS Life Sciences Group, Inc. estimates its unaudited cash and cash equivalents position at $71.8 million[4] - The company received approximately $26.5 million in proceeds from the exercise of common stock warrants after December 31, 2025[5] Share Information - As of January 7, 2026, the company had 170,282,026 shares of common stock outstanding[6]